- $106.31m
- $86.28m
- $19.61m
Brief: Icad Inc- Repaid Obligations In Amount Of $7.4 Mln Under And Terminated Its Loan And Security Agreement Entered Into On March 30, 2020
Brief: Icad Q1 Loss Per Share $0.07
Icad Inc Expected To Post A Loss Of 12 Cents A Share: Earnings Preview
ICAD Inc: Rises on upbeat Q1 revenue forecast
U.S. RESEARCH ROUNDUP-Acadia Pharmaceuticals, Booking Holdings, Tripadvisor
Brief: iCAD Sees Q1 Revenue More Than $8.1 Million
ICAD: Jumps on FDA nod for new version of mammography software
Brief: Icad Announces FDA Clearance For Profound Ai Version 3.0 For 3D Mammography
Brief: Icad Announces Closing Of $25.0 Million Public Offering
Brief: iCAD Announces Pricing Of $22 Mln Public Offering Of Common Stock
Brief: ICAD Announces Proposed Public Offering Of Common Stock
Brief: iCAD Reports Q4 Financial Results
Brief: ICAD Inc Reports Over 1,000 Licenses Sold As Part Of Profound AI Sales
Brief: iCAD Signs Distribution Agreement with Change Healthcare
ICAD: Colliers cuts PT as CMS excludes co's new radiation therapy
Brief: Icad’S Iort Excluded From CMS’S Radiation Oncology Alternative Payment Model
Brief: iCAD Reports Financial Results For Second Quarter And Six Months Ended June 30, 2020
Brief: Icad Inc - Profound Ai Risk Received A CE Mark In Europe
Brief: ICAD Added To Russell 2000 Index